53234-67-6

Upstream product

• 110-91-8 morpholine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 104763-55-5 5-benzyl-7a-morpholin-4-yl-1-phenyl-3a,4,5,6,7,7a-hexahydro-1H-[1,2,3]triazolo[4,5-c]pyridine 
• 110523-76-7 6-benzyl-2-phenyl-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridin-4-one 
• 54568-58-0 1-(morpholin-4-yl)-3-phenylpropane-1,3-dione 
• 98-86-2 acetophenone 
• 110523-74-5 2-benzyl-1,2,3,4,5,6,7,8-octahydro-2-azaxanthone 
• 28637-51-6 morpholine amide of 2-carboxycyclohexanone 
• 144774-11-8 6-benzyl-2-ethyl-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridin-4-one 
• 40240-12-8 1-benzyl-1,2,3,6-tetrahydropyridine 
• 132532-25-3 1α,5α,6β-3-benzyl-6-morpholino-3-azabicyclo<3.1.0>hexane-6-carbonitrile 
• 54629-30-0 10H-benzopyrano[3,2-c]pyridin-10-one 
• 132532-20-8 4-(1-benzyl-3-chloro-1,2,3,6-tetrahydro-4-pyridyl)-morpholine 
• 28637-50-5 morpholine amide of 3-carboxy-2-butanone 
• 110523-75-6 2-benzyl-2,3-dimethyl-5,6,7,8-tetrahydro-6-azachromone 
• 78-93-3 butanone 

Relevant academic research and scientific papers

Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold

Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) plays a key role in one-carbon (1C) metabolism in human mitochondria, and its high expression correlates with poor survival of patients with various types of cancer. An isozyme-selective MTHFD2 inhibitor is highly attractive for potential use in cancer treatment. Herein, we disclose a novel isozyme-selective MTHFD2 inhibitor DS44960156, with a tricyclic coumarin scaffold, which was initially discovered via high-throughput screening (HTS) and improved using structure-based drug design (SBDD). DS44960156 would offer a good starting point for further optimization based on the following features: (1) unprecedented selectivity (>18-fold) for MTHFD2 over MTHFD1, (2) a molecular weight of less than 400, and (3) good ligand efficiency (LE).

Cyclic amino compounds

A cyclic amino compound represented by the following formula: or a pharmacologically acceptable salt thereof. R1is a substitutable phenyl group. R2is a substitutable aliphatic acyl group, a substitutable benzoyl group or an alkoxycar

Synthesis of 3-azabicyclo[3.3.1]Nonane-6,9-diones

A one pot synthesis of 3-azabicyclo[3.3.1]nonane-6,9-diones is described via the additibn of acryloyl chloride to enamines of N-carboxy-4 piperidones. Yields of bicycle were highest when additions were made to vigorously boiling solutions of morpholine en

Cyclic amine derivatives

A cyclic amine derivative represented by the following formula: wherein R1 represents a substituted or unsubstituted phenyl group, R2 represents a substituted of unsubstituted C1-C8 aliphatic acyl group, a substituted or unsubstituted benzoyl group or a C1-C4 alkoxycarbonyl group, and R3 represents a substituted 3 to 7 membered saturated cyclic amino group which may form a fused ring; or pharmaceutically acceptable salts thereof. The compounds and salts have excellent platelet aggregation inhibitory action. They are useful for the treatment and prevention of such diseases as embolism, thrombosis or arteriosclerosis and for the preparation of pharmaceutical compositions for such uses.